Diversity and level of evidence evaluation of commercial pharmacogenomic testing for mental health
Morosoli, J. J.; Lind, P. A.; Spears, K.; Pratt, G.; Medland, S. E.
Show abstract
This study examined arrays offered by commercial pharmacogenomic (PGx) testing services for mental health care in Australia and the United States, with a focus on utility for non-European populations. Seven of the 14 testing services we identified provided the manifests of their arrays. We examined allele frequencies for each variant using data from the Allele Frequency Aggregator1 (ALFA), genome Aggregation Database2 (gnomAD), Exome Aggregation Consortium2 (ExAC), and Japanese Multi Omics Reference Panel3, and examined genetic heterogeneity. We also analyzed meta-data from the Pharmacogenomic Knowledge Base4 (PharmGKB) and explored the biogeographical origin of supporting evidence for clinical annotations. Most arrays included the minimum allele set recommended by Bousman et al5. However, few arrays included HLA-A or HLA-B. The most diverse allele frequencies were seen for variants in CYP3A5, ADRA2A and GNB3, with European and African populations showing the largest differences. Most evidence listed in PharmGKB originated from European or unknown ancestry samples.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- OCTAD: an open workplace for virtually screening therapeutics targeting precise cancer patient groups using gene expression features 87%
- A Methodological Checklist for fMRI Drug Cue Reactivity Studies: Development and Expert Consensus 85%
- Integration of diverse bioactivity data into the Chemical Checker compound universe 84%
Similar papers in this journal
Similar papers in this journal
- Evidence for a serotonergic subtype of major depressive disorder: A NeuroPharm-1 study. 91%
- A Survey of Copy Number Variants Associated with Neurodevelopmental Disorders in a Large-Scale, Multi-Ancestry Biobank 90%
- Decoding Treatment Choice: Genetic and Phenotypic Analyses of Long-term Antidepressant Acceptability 89%
Similar papers in this journal
- Whole-genome sequencing analysis of clozapine-induced myocarditis 95%
- Cyrius: accurate CYP2D6 genotyping using whole genome sequencing data 93%
- Investigating an in-silico approach for prioritizing antidepressant drug prescription based on drug-induced expression profiles and predicted gene expression 91%
Similar papers in this journal
- Leveraging genome-wide data to investigate differences between opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium 91%
- Genetic Analysis of Psychosis Biotypes: Shared Ancestry-Adjusted Polygenic Risk and Unique Genomic Associations 90%
- Molecular phenotypes associated with antipsychotic drugs in the human caudate nucleus 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.